Heparin-induced thrombocytopenia (HIT II) – A drug-associated autoimmune disease

 

PDF Download Buy Article Permissions and Reprints

Summary

Autoimmune thrombocytopenia (ITP) is an acquired autoimmune disease characterised by isolated persistent thrombocytopenia and normal megakaryopoiesis. This definition also applies to heparin-induced thrombocytopenia (HIT II), a frequent side effect of heparin treatment. In HIT II, the immunogen is a coagulation active complex of heparin and platelet factor 4 (PF4). By now, diagnostics of HIT II is often material and time consuming. Three groups of patients were investigated for HIT II antibodies (HIT II-AB): 54 hospitalised stroke patients, 87 hospitalised cardiac patients, and 71 patients on chronic haemodialysis, all treated with heparin. Furthermore, 100 healthy volunteers were investigated. For detection of HIT II-AB the innovative whole blood test PADA-HIT (PADA: platelet adhesion assay) was used. PADA-HIT quantifies the interaction of IgG antibodies with FcγIIA receptors by comparing the activation state of platelets in citrated and heparinised whole blood. The occurrence of HIT II-AB in blood was very high with 44 % of stroke patients, 69% of cardiac patients and 38% of haemodialysis patients compared to only 15% of healthy volunteers. This demonstrates a high incidence and a rapid onset of HIT II-AB in patients being acutely treated with heparin. HIT II is one of the most frequent and severe autoimmune diseases bearing a great thrombosis risk. PADA-HIT represents an innovative diagnostic method for detection of autoimmune antibodies of IgG type that are directed against platelet factor 4 (PF4)-heparin-complex. By early and fast diagnostics and appropriate treatment severe complications of HIT II can be prevented.

• References

• 1 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8^th Edition). Chest 2008; 133: 340S-380S.
  CrossrefPubMedGoogle Scholar
• 2 Davoren A, Ster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81: 36-44.
  CrossrefPubMedGoogle Scholar
• 3 Kanaan AO, Al-Homsi AS. Heparin-induced thrombocytopenia: pathophysiology, diagnosis, and review of pharmacotherapy. J Pharm Pract 2009; 22: 149-157.
  CrossrefPubMedGoogle Scholar
• 4 Zinkowsky DA, Antonopoulos MS. Heparin-induced thrombocytopenia: overview and treatment. PT 2008; 33: 642-652.
  PubMedGoogle Scholar
• 5 Bennett-Guerrero E, Slaugher TF, White WD. et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005; 130: 1567-1572.
  CrossrefPubMedGoogle Scholar
• 6 Greinacher A, Juhl D, Strobel U. et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of platelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 05: 1666-1673.
  CrossrefPubMedGoogle Scholar
• 7 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 311-337.
  PubMedGoogle Scholar
• 8 Greinacher A, Levy IH. HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia. Anaesth Analg 2008; 107: 356-358.
  CrossrefPubMedGoogle Scholar
• 9 Rosenberg N, Einav Y, Shenkman B. Autoimmune Thrombocytopenic Purpura. In: Diagnostic Criteria in Autoimmune Diseases. Humana Press; Totowa (USA): 2008: 543-546.
  Google Scholar
• 10 Blank M, Shoenfeld Y, Tavor S. et al. Anti-platelet factor 4/heparin antibodies from patients with heparininduced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14: 121-129.
  CrossrefPubMedGoogle Scholar
• 11 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
  CrossrefPubMedGoogle Scholar
• 12 Greinacher A, Kohlmann T, Strobel U. et al. The temporal profile of the anti-PF/heparin immune response. Blood 2009; 113: 4970-4976.
  CrossrefPubMedGoogle Scholar
• 13 Chan M, Malynn E, Shaz B. et al. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hemat 2008; 83: 420-423.
  CrossrefPubMedGoogle Scholar
• 14 Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
  CrossrefPubMedGoogle Scholar
• 15 Aster RH. Heparin-independent activation of platelets by HIT antibodies: a clue to the etiology of delayed thrombocytopenia/thrombosis in patients given heparin?. J Thromb Haemost 2005; 03: 2166-2167.
  CrossrefPubMedGoogle Scholar
• 16 Ulbricht K, Bucha E, Pöschel KA. et al. The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters. Clin Nephrol 2006; 65: 180-190.
  CrossrefPubMedGoogle Scholar